Claims:

1. A composition comprising:
sirolimus present in an amount ranging from about 1 wt% to about 10 wt%, based on weight of the composition;
sucrose acetate isobutyrate (SAIB) present in an amount ranging from about 0.1 wt% to about 10 wt%, based on weight of the composition;
benzyl benzoate present in an amount ranging from about 30 wt% to about 60 wt%, based on weight of the composition;
ethanol present in an amount ranging from about 1 wt% to about 10 wt%, based on weight of the composition;
polyethylene glycol (PEG) present in an amount ranging from about 30 wt% to about 60 wt%, based on weight of the composition; and
vitamin E present in an amount ranging up to 5 wt%, based on weight of the composition.

2. The composition of claim 1, wherein:
the composition comprises from 1 wt% to 5 wt% of the sirolimus, based on weight of the composition.

3. The composition of any one of claims 1 and 2, wherein the benzyl benzoate is present in an amount ranging from 35 wt% to 45 wt%, based on weight of the composition.

4. The composition of any one of claims 1 to 3, wherein:
the ethanol is present in an amount ranging from 1 wt% to 7 wt%, based on weight of the composition.

5. The composition of any one of claims 1 to 4, wherein
the PEG is present in an amount ranging from 35 wt% to 50 wt%, based on weight of the composition, or from 40 wt% to 50 wt%, based on weight of the composition.

6. The composition of any one of claims 1 to 5, wherein (a) the vitamin E is present in an amount ranging from 0.5 wt% to 2 wt%, based on weight of the composition; or (b) the composition has a weight ratio of SAIB:vitamin E ranging from 0.5 to 10.

7. The composition of claim 1, wherein:

(A) the vitamin E is present in an amount ranging from 0.1 wt% to 5 wt%, based on weight of the composition;

and preferably wherein:

(B) the sirolimus is present in an amount ranging from 1 wt% to 5 wt%, based on weight of the composition;
the benzyl benzoate is present in an amount ranging from 30 wt% to 45 wt%, based on weight of the composition;
the PEG is present in an amount ranging from 40 wt% to 50 wt%, based on weight of the composition; and
the vitamin E is present in an amount ranging from 0.5 wt% to 2 wt%, based on weight of the composition;

and more preferably wherein:

(C) the composition consists essentially of:
sirolimus in an amount ranging from 1 wt% to 5 wt%, based on weight of the composition;
SAIB in an amount ranging from 0.1 wt% to 10 wt%, based on weight of the composition;
benzyl benzoate in an amount ranging from 30 wt% to 45 wt%, based on weight of the composition;
ethanol in an amount ranging from 1 wt% to 10 wt%, based on weight of the composition;

PEG400 in an amount ranging from 40 wt% to 50 wt%, based on weight of the composition; and

vitamin E in an amount ranging from 0.5 wt% to 2 wt%, based on weight of the composition.

8. The composition of claim 1, the composition consisting essentially of:

sirolimus in an amount ranging from 1 wt% to 5 wt%, based on weight of the composition;

SAIB in an amount not exceeding 10 wt%, based on weight of the composition;

benzyl benzoate;

ethanol and PEG400; and

vitamin E in an amount ranging from 0.5 wt% to 2 wt%, wherein a weight ratio of SAIB to vitamin E exceeds 0.5.

9. The composition of any one of claims 1 to 8, wherein the composition is pharmaceutically acceptable, and preferably wherein the composition is formulated for injection.

10. The composition of claim 1, which comprises

sirolimus in an amount of about 3 wt%, based on weight of the composition

SAIB in an amount of about 1 wt%, based on weight of the composition;

benzyl benzoate in an amount of about 43.7 wt%, based on weight of the composition;

ethanol in an amount of about 4.8 wt%, based on weight of the composition;

PEG400 present in an amount of about 46.5 wt%, based on weight of the composition; and

vitamin E in an amount of about 1 wt%, based on weight of the composition.

11. A composition as defined in any one of claims 1 to 10 for use as a medicament.

12. A composition as defined in any one of claims 1 to 10 for use in treatment of an eye condition, wherein the active pharmaceutical ingredient comprises an ophthalmic drug,

and preferably wherein the eye condition comprises uveitis, diabetic macular edema, or wet age-related macular degeneration.